US 12478642 B1Patent grantUnited States

Calcium-Vanadate Nanocomposite for Cancer-Cell Screening

Official patent title

Method of treating cancer using CaV2O6/CaSiO3/g-C3N4 nanocomposite

Arabic title: طريقة لعلاج السرطان باستخدام المركب النانوي CaV2O6/CaSiO3/g-C3N4

Invention

Problem

Cancer treatment research needs agents that reduce malignant-cell viability while sparing normal tissue. Activity in cultured cells is an early screen and does not establish a safe or effective therapy.

Why it matters

A porous inorganic/carbon-nitride composite with measurable dose-dependent cell responses can provide a lead for mechanism, selectivity, uptake, and toxicology studies.

Approach

The method contacts HepG-2 hepatocellular-carcinoma or MCF-7 breast-carcinoma cells with a CaV2O6/CaSiO3/g-C3N4 nanocomposite at 36–38 °C for 12–48 hours.

Who may benefit

Potential beneficiaries include oncology laboratories, nanomedicine researchers, pharmaceutical discovery groups, toxicologists, and advanced-material developers.

Potential value

The disclosure combines a defined porous CaV2O6/CaSiO3/g-C3N4 material with claimed dose–response and IC50 thresholds in two human cancer-cell lines.

Background

Nanocomposites can affect cancer cells through surface interactions, ion release, oxidative stress, or other mechanisms. Cultured-cell viability assays can identify concentration-dependent responses, but they do not establish tumor selectivity, biodistribution, tolerability, or efficacy in a living organism. The material also contains vanadium, making release and systemic toxicology important. The patent reports responses in HepG-2 and MCF-7 cultures and uses the language of apoptosis, but the supplied evidence remains in vitro and preclinical.

Technology overview

The composite includes calcium metavanadate, calcium silicate, and graphite-phase carbon nitride, with 0.18–0.26 cm³/g pore volume and 55–60 m²/g BET area. It is synthesized from separate silicate, carbon-nitride, and vanadate products followed by microwave treatment. Claims specify contact at 3 µg/mL or more, 36–38 °C, and 12–48 hours. IC50 limits are 123 µg/mL or less for MCF-7 and 93 µg/mL or less for HepG-2, with additional viability ranges at stated concentrations.

Potential applications

In-vitro cancer-cell viability research.
Nanocomposite apoptosis-mechanism studies.
Preclinical uptake and selectivity screening.
Experimental oncology material development.

Evidence-supported advantages

Provides dose-linked viability ranges for two cell lines.
States IC50 thresholds for MCF-7 and HepG-2.
Uses a porous, structurally defined composite.
Provides a multi-step synthesis route.
Supports follow-on mechanism and selectivity studies.

Development stage

Material synthesis, characterization, and in-vitro cancer-cell viability measurements are described; normal-cell selectivity, animal safety and efficacy, clinical testing, and commercialization were not established. The development stage was not independently verified.

Commercial opportunity

The material is an early in-vitro lead. Progress requires independent assay replication, normal-cell selectivity, apoptosis-mechanism confirmation, vanadium and calcium release, genotoxicity and immunotoxicity, pharmacokinetics, formulation and administration development, animal efficacy and tolerability, scalable quality-controlled synthesis, and regulatory review before human use.

Patent classifications

WIPO IPC

A61K33/44Preparations for medical, dental or toiletry purposes

CPC

A61K33/44Preparations for medical, dental or toiletry purposes

Inventors

First inventorMohamed Khairy Abdel Fattah Omran
InventorBabiker Yagoub Elhadi Abdulkhair

Keywords

CaV2O6
CaSiO3
graphitic carbon nitride
HepG-2
MCF-7
apoptosis
in vitro
nanocomposite

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.